Urgent Report From The Oxford Club’s Editorial Director:

“I See a 4,150%Earnings Setup inThis $7 Biotech”

Thanks to a Rare Deal With the CDC, This TinyBiotech Is Poised to Capture a $22.1 BILLION

Market... Starting With a Special Event onJanuary 14, 2015

Dear Reader,

On January 14, 2015, the world’s top biotech investors will meet in a private conference toreveal their best new ideas for the industry.

This year, executives at a tiny biotech trading for only $7 will make one of the most importantpresentations.

They will talk about a radical technology the company has developed that could dramaticallychange the way doctors and hospitals operate... and it could kick off a major run in the companystock.

Yet, for the moment, most Americans have never heard of this company... it’s seemingly comingout of nowhere.

But that won’t last long...

In a landmark move, the Centers for Disease Control and Prevention (CDC) is planning ongiving this tiny company a virtual monopoly by awarding it a sole source contract.

A sole source contract means this company is the only one in existence that can provide thisservice, and the CDC will never accept competing bids from other companies.

As the CDC puts it, this company’s technology has a “new and unique process we require for ourresearch.” It goes on to say that it’s the ONLY way this company can complete its landmarkAdvanced Molecular Detection project to protect U.S. citizens from the threat of infectiousdiseases.

As the most powerful public health branch of the government, the CDC rarely makes moves likethis.

So why is there such a great desire for this company’s technology?

As you may know, when you go to the doctor, you seldom get answers right away.

It takes tests, appointments, specialists and more tests before anything useful is accomplished.The process can last weeks, even months.

This company is about to change all that.

In short, it’s developed a new gene-sequencing technology that could soon be used to tell youwhat disease you are likely to get months, or even years, in advance.

Instead of all the tests, discussions of symptoms and guesswork that go into a diagnosis, thistechnology can analyze your specific genes and assist doctors in diagnosing possible healthissues.

I’m talking about health issues like...

Heart disease

Type 2 diabetes

Alzheimer’s disease

Breast cancer

Crohn’s disease

Celiac disease

Colon cancer

Heart attack

Glaucoma

Osteoarthritis

Prostate cancer

Rheumatoid arthritis

Stomach cancer

All of these diseases have a single factor in common: They are hard to stop once they reach laterstages. But they can be very manageable when recognized early.

This company is on its way to doing that... and it does it far better than anyone else.

In fact, you get a 10 to 20 times longer sequence and 55% more genetic information using itsproduct.

In fact, Dr. Evan Eichler of the Howard Hughes Medical Institute claims it may now make itpossible for researchers to “identify potential genetic mutations behind many conditions.”

That means you could spot far more problems well in advance. It’s like having a pair ofbinoculars for future health problems.

That gives this company an edge in the market far above its competitors.

And it is about to make a lot of money as a result.

A study by Grand View Research shows the genomics market will grow to $22.1 BILLION in thenext five years.

Right now, this company (at the forefront of it all) has annual sales of just $52 million.

And thanks to the CDC’s plan to award this company its exclusive sole source contract, it is setto capture an unprecedented share of this growing market.

Even better, the company recently partnered with Roche - one of the world’s largestpharmaceuticals - to develop new diagnostic products for everyday clinical use.

It doesn’t take a mathematical genius to tell you this company’s revenue is about to see aspectacular surge.

If it captures just one-tenth of this market, it could see sales surge by an astounding 4,150%.

Why am I so convinced this will happen?

And why is this different from any other stock reports you’ve read touting big returns?

My answer is simple: The company is following a plan that’s proven to work... as I’ll show you ina moment.

The BioTech LifeCycleMy name is Andrew Snyder.

I’m the Editorial Director of Investment U Daily. Each day, more than 200,000 individuals,hedge fund managers, CEOs and institutions rely on our timely information.

My job is to comb through our articles... and ensure we publish the most timely and potentiallyprofitable investment ideas.

The company I’m alerting you to today was discovered by our resident biotech expert and ChiefIncome Strategist Marc Lichtenfeld.

When he showed me this opportunity, I knew he had found something special.

Rarely have I seen a situation with as much profit potential.

You see, this $7 biotech is not simply making its way into uncharted territory here.

Rather, it is following a tried-and-true process proven to take certain biotech stocks to untoldheights.

We call this pattern “The BioTech LifeCycle.”

Let me show you how this cycle works...

PHASE 1: The Fanfare Launch

The first phase of the LifeCycle is a fanfare launch.

Many biotechs start with great ideas. They IPO with tremendous excitement and everyonebelieves they’re going to be the next “get rich quick” stocks.

Illumina is the perfect example - especially considering this $7 stock is following its trajectoryalmost exactly.

Before Illumina’s IPO, people were crazy about gene-sequencing technology.

They expected this technology to change the world... to map a person’s genome for under$1,000.

Even President Bill Clinton put in his two cents on the first draft of the human genomesequence, saying, “Humankind is on the verge of gaining immense, new power to heal... It willrevolutionize the diagnostic, prevention and treatment of most, if not all, human disease.”

So when Illumina launched, investors went crazy buying shares...

And it jumped 26% in a few days:

The same thing happened with our $7 biotech when it launched...

Lots of prominent publications touted their technologies as the next step in gene-sequencing...

The American Institute of Physics proclaimed, “The device is being developed to sequence DNAat speeds 20,000 times faster than second-generation sequencers currently on the market andwill ultimately have a price tag of $100 per genome.”

Yu-Hui Rogers, scientific director of the J. Craig Venter Joint Technology Center, said the $7stock’s technology was “potentially revolutionary.” The company’s founder predicted it wouldbe the first to “deliver the 15-minute human genome.”

So soon after it IPO’d, investors again rushed in to buy shares.

You’ll see it looks almost exactly like Illumina:

Now, here’s what’s important...

Most biotechs go through this “fanfare” phase at the beginning. This phase of the LifeCycle isnecessary to raise money for the company so it can get its products to market, but it doesn’tmean it’ll automatically start making money... which leads to the second phase in the BioTechLifeCycle...

PHASE 2: Development LullMost people don’t realize that a biotech company goes public not to make money, but to fund itsbusiness’s growth.

After the IPO, biotechs take all that money they received through their public offerings and useit to develop their products.

This means marketing, making deals, getting FDA approval, buying new equipment...

But it also is a period without much revenue growth.

As a result, biotech companies often lose their launch momentum and slide slowly downward inprice.

You can see that here with Illumina...

Investors piled into the stock at first... but shortly after, it plummeted when investor’s revenueexpectations weren’t immediately met.

For the next few years, the stock went flat as Illumina used its new capital to research anddevelop its product.

This is the exact same thing that’s happening to our $7 biotech:

It jumped soon after its IPO... dropped as investors got restless... and has been generally flat asit’s used this capital to finalize its product.

And that brings us to Phase 3 of the BioTech LifeCyle...

PHASE 3: The RebirthAfter all the time and money spent building up the product pipeline, everything finally comestogether.

The products hit the open market.

The deals are made.

And most importantly, revenues go flying up.

As a result, the stock has a rebirth, and shoots up the charts.

That’s what happened to Illumina.

Its revenues jumped from $19.5 million to $53.5 million... an increase of 174%.

It made strategic partnerships with its competitors... and launched seven new products in thespan of a year.

Forbes named it the No. 1 fastest-growing high-tech company in the United States as ittransitioned into profitability.

An analyst at Pacific Growth Equities put it best, saying, “Illumina was starting to get to a pointas a company where they were more mature and had significant earnings.”

If you had bought in a few months before this was happening, you could have watched as thestock rose over 3,950%:

Imagine that... $5,000 invested before the beginning of the third phase would now be worthover $197,500!

I’ve seen this happen over and over again in the highest-returning biotech companies.

Like Questcor Pharmaceuticals...

The year it IPO’d, Questcor’s stock jumped in Phase 1...

It fell when the hype died off and the stock went flat in Phase 2...

And after establishing its product, the stock ignited in Phase 3... giving investors anextraordinary 12,000% gain.

Just $5,000 invested at the beginning of Phase 3 would now be worth over $600,000.

The same situation that happened to Illumina and Questcor Pharmaceuticals is happening inour $7 biotech RIGHT NOW...

Its revenues just jumped from $7 million to $20 million... an increase of 178%.

It’s filed an astounding 161 U.S. patents since 2009.

The Wall Street Journal ranked it No. 1 among venture-backed companies.

Yet the biggest catalyst is this...

It is expected to receive an exclusive sole source contract from the CDC so the government canbetter understand the human genome, possibly leading to solutions for diseases like Ebola andmeningitis.

What’s most remarkable about this company’s product is its ability to give a detailed analysis ofspecific genes... far and above any of its competitors.

In fact, you get 55% more genetic information using its product... That means you must havethis machine to get the most comprehensive DNA or RNA sequence available to date.

That gives this company a practical monopoly in this niche.

Even if it captures only one-tenth of the expected $22.1 billion genetic research market, it couldsee sales surge by an astounding 4,150%.

We expect that number to be much higher. Let me show you why...

A Milestone Partnership With RocheThis small company is targeting what could be the most lucrative sector in the gene-sequencingindustry - the personal diagnostics market.

You see, current gene sequencers are used primarily for research - not for diagnosing individualpatients.

Yet the market for personal diagnostics currently stands at $232 billion. And it’s projected togrow at a double-digit rate annually.

This company’s technology is tapping directly into this market.

And in a milestone move, Roche - one of the largest pharmaceutical companies in the world -has established a multimillion-dollar partnership with the company to produce new personaldiagnostic machines for doctors, hospitals and clinics.

Currently, there are 5,723 hospitals in America. Based on sales estimates, if only a quarter ofthese hospitals buy this company’s machine, it could bank an approximate $1.144 BILLIONwindfall.

Considering its new partnership with Roche, this will be the go-to company for this technology...and it could result in an unimaginable stock run-up that will reward early investors handsomely.

Just consider... this company’s technology is required to get the most comprehensive view of thehuman genome.

As I said earlier, the CDC says that its technology has a “new and unique process werequire for our research.” And that it is “the only way to successfully complete ourgenome-sequencing project.”

The closest thing I can compare it to is the emergence of photography...

Data from current gene sequencers comes out like an impressionist painting. You get the bigpicture, but few details.

But our $7 biotech’s newest sequencer gives a high-def 30-megapixel photograph.

It captures incredible details of a gene’s structure. And it gives its clients a fuller and moreuseful sequence... so it can spot potential health problems on the spot.

It’s easy to see why this company is getting huge orders from the CDC, big pharmaceuticals,hospitals and research labs across the globe.

But here’s what will really kick off the gains...

Here’s Why You Need to Get In BeforeJanuary 14, 2015...

In biotech stocks, there’s often a major catalyst that kicks off massive gains.

And it often involves big announcements at J.P. Morgan’s invitation-only biotech investmentconference held once a year.

To show you what I mean, take a look at Illumina’s chart again.

On January 12, 2004, it gave a presentation at this investment conference...

And it helped boost the stock toward a massive 3,950% climb as big investors cascaded into thestock after the conference.

Now, our $7 biotech is set to make one of the key presentations at the J.P. Morgan conference.

No doubt it will reveal the extent to which its technology is about to be used throughout thecountry, and how much money it’s likely to bring in.

And it will kick off the final phase of the BioTech LifeCycle... sending its shares flying higher.

You’ll want to get in before this happens.

That’s why I want to immediately send you a free copy of my report: “This $7 Biotech StockHas a 4,150% Setup.”

We’ve developed a package that reveals everything you need to know about this incrediblecompany.

You’ll get the name and ticker symbol. You’ll find out exactly how to play it for maximum gains.

Download Our Urgent ReportTo claim your free copy of “This $7 Biotech Stock Has a 4,150% Setup,” all you need to dois simply give Investment U Plus a try.

Investment U Plus is a special enhanced version of our Investment U Daily newsletter thatcontains specific recommendations from our top experts.

We take the regular articles... and then supplement the information with the toprecommendations from our editors’ VIP Trading Services.

For example, I cherry-picked this $7 biotech company from our Chief Income Strategist MarcLichtenfeld’s $5,000-a-year investment service, Lightning Trend Trader.

What’s more, you’ll receive similar recommendations with each and every issue of Investment U

Daily, as part of your Investment U Plus benefits.

You see, not only has Marc agreed to share his top recommendations from his paid, premiumresearch... but so have all our top experts.

So you’ll get all the top picks from...

Alexander Green’s True Value Alert ($4,500 value)... Insider Alert ($4,995 value)...and Momentum Alert ($4,995 value)

Marc Lichtenfeld’s Lightning Trend Trader ($4,995 value)... Dividend Multiplier($2,500 value)... and Oxford Systems Trader ($5,500 value)

Steve McDonald’s Oxford Bond Advantage ($4,995 value)

Matthew Carr’s Emerging Trends Trader ($4,500 value)

David Fessler’s Peak Energy Strategist ($1,100 value) and Peak Energy Trader($2,000 value)

And Sean Brodrick’s brand-new $10 Trigger Alert ($5,000 value).

Normally, it would cost more than $45,000 to subscribe to all these premium research services.

And many people would be happy to pay that much.

But, when you join Investment U Plus, you’ll pay a tiny fraction of that to get some of theVERY BEST PICKS from all these services.

We’ve done this so you can experience just how lucrative some of the premium service picks canbe.

And we’re doing it at a “can’t say no” price, because we know once you experience theprofitability of recommendations like the $7 stock I talked about today, you’ll stick with us forsome time.

That’s why you can upgrade your subscription today to Investment U Plus for just $4.99 amonth.

Subscribing to Investment U Plus could be the smartest investment you’ll make this year –and certainly the most economical.

As subscriber Michael Marrien says, “To get a peek at your expert picks from your expensivetrading services at $5 a month is a great deal. So thank you for a great product.”

When you become an Investment U Plus subscriber, you’ll receive...

“This $7 Biotech Stock Has a 4,150% Setup”: I’ll immediately send you my specialreport that gives you full details on this radical new company that’s set for a dramatic rise.You’ll get the name and ticker symbol so you can get shares as soon as the markets open.

Top Picks From Our Experts: You’ll get more picks from Investment U Plus in onemonth than you would get in a whole year from most premium research services. Each

week, our experts will give you their absolute best picks and plays delivered straight toyour email and accessible on your upgraded Investment U Plus website.

Private Website Access: As soon as you subscribe, you’ll get full access to yourInvestment U Plus password-protected website. There, we’ll archive every one of ourplays online. They’re available 24 hours a day on a site you can access anywhere. So you’llnever risk missing a single gain.

If you sign up today, you’ll also get two additional bonus reports:

Report #1: “How to Build a Million-Dollar Portfolio From Scratch” – This reportreveals seven real secrets for successful investing. You’ll find out each one, and how youcan build a million-dollar portfolio starting with almost nothing. You’ll learn about oneproven investment strategy that’s accounted for nearly 90% of all returns in the stockmarket. And you’ll find out the only way to secure a built-in “safeguard” against anymarket downturn. What’s more, the report will show you the most common mistakesinvestors make, and how to avoid them.

Report #2: “The Gone Fishin’ Portfolio” – This report details a simple, long-terminvestment system based on a Nobel Prize-winning approach. It takes only 20 minutes peryear to implement its strategy, but it’s currently showing an average gain of 167% on its 10positions. This portfolio is set up for people who just don’t want to worry about theirmoney. It’s a “set it and forget it” portfolio that delivers great returns without theheadaches.

Upgrade Now to Get $45,080 Worth ofOur Best Investment Ideas for Just $4.99

If you upgrade to Investment U Plus today, I will immediately send you your two bonusreports and, of course, our special report “This $7 Biotech Stock Has a 4,150% Setup.”

You’ll also lock in our special $4.99 monthly rate for as long as you’re a subscriber.

And you’re completely free to cancel at any time. Simply give us a call, and we’ll cancel yoursubscription immediately.

But once you try out Investment U Plus, I’m certain you’ll want to keep going.

After all, where else can you get $45,080 worth of stock picks for such a low cost?

All you have to do is click “SUBSCRIBE NOW” below.

Sincerely,

Andrew SnyderEditorial Director, The Oxford Club

P.S. Remember, you’ll want to read my report before January 14, 2015. Once momentumstarts in this stock, it could move VERY QUICKLY. So I urge you to get your report immediately.Click “SUBSCRIBE NOW” below.

SUBSCRIBE NOW

SUBSCRIBE NOW